CN113329691B - 防血凝块附着剂和血液采集容器 - Google Patents
防血凝块附着剂和血液采集容器 Download PDFInfo
- Publication number
- CN113329691B CN113329691B CN202080010053.5A CN202080010053A CN113329691B CN 113329691 B CN113329691 B CN 113329691B CN 202080010053 A CN202080010053 A CN 202080010053A CN 113329691 B CN113329691 B CN 113329691B
- Authority
- CN
- China
- Prior art keywords
- blood
- clot
- collection container
- blood collection
- adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 116
- 239000008280 blood Substances 0.000 title claims abstract description 116
- 239000000853 adhesive Substances 0.000 title claims abstract description 56
- 230000001070 adhesive effect Effects 0.000 title abstract description 49
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 103
- 150000001413 amino acids Chemical class 0.000 claims abstract description 44
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 38
- 229920000570 polyether Polymers 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 210000002966 serum Anatomy 0.000 claims description 44
- 229940024606 amino acid Drugs 0.000 claims description 43
- 235000001014 amino acid Nutrition 0.000 claims description 43
- 239000000843 powder Substances 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 238000000926 separation method Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
- 230000023555 blood coagulation Effects 0.000 claims description 19
- 239000012790 adhesive layer Substances 0.000 claims description 17
- 230000001737 promoting effect Effects 0.000 claims description 15
- 229920001451 polypropylene glycol Polymers 0.000 claims description 13
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 9
- 150000002334 glycols Chemical class 0.000 claims description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 5
- 101000772006 Bombus ignitus Venom serine protease Bi-VSP Proteins 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 235000009582 asparagine Nutrition 0.000 claims description 5
- 229940000635 beta-alanine Drugs 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 108090000190 Thrombin Proteins 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 229960004072 thrombin Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920002545 silicone oil Polymers 0.000 abstract description 45
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 239000010410 layer Substances 0.000 description 23
- 239000003921 oil Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- -1 glycol ethers Chemical class 0.000 description 9
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 8
- 239000007788 liquid Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 125000001033 ether group Chemical group 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- UAFHRUBCOQPFFM-UHFFFAOYSA-N 1-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NCC1(C(O)=O)CCCCC1 UAFHRUBCOQPFFM-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000909 polytetrahydrofuran Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000790 scattering method Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003232 water-soluble binding agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/15003—Source of blood for venous or arterial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150343—Collection vessels for collecting blood samples from the skin surface, e.g. test tubes, cuvettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
- A61B5/154—Devices using pre-evacuated means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0047—Enzymes, e.g. urokinase, streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/02—Use of inorganic materials
- A61L33/027—Other specific inorganic materials not covered by A61L33/022 or A61L33/025
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/04—Use of organic materials, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/062—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
- A61L33/128—Other specific proteins or polypeptides not covered by A61L33/122 - A61L33/126
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
- B01L3/50215—Test tubes specially adapted for centrifugation purposes using a float to separate phases
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/10—Block- or graft-copolymers containing polysiloxane sequences
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D183/00—Coating compositions based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon only; Coating compositions based on derivatives of such polymers
- C09D183/10—Block or graft copolymers containing polysiloxane sequences
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D7/00—Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
- C09D7/40—Additives
- C09D7/60—Additives non-macromolecular
- C09D7/63—Additives non-macromolecular organic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/0096—Material properties self cleaning, e.g. having lotus effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/16—Reagents, handling or storing thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/042—Caps; Plugs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0848—Specific forms of parts of containers
- B01L2300/0858—Side walls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/16—Surface properties and coatings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/42—Block-or graft-polymers containing polysiloxane sequences
- C08G77/46—Block-or graft-polymers containing polysiloxane sequences containing polyether sequences
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/16—Nitrogen-containing compounds
- C08K5/17—Amines; Quaternary ammonium compounds
- C08K5/175—Amines; Quaternary ammonium compounds containing COOH-groups; Esters or salts thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Ecology (AREA)
- Clinical Laboratory Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Hydrology & Water Resources (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
本发明提供能够抑制血凝块附着至血液采集容器的内壁面的防血凝块附着剂。本发明的防血凝块附着剂包含:聚醚化合物或硅油;氨基酸。
Description
技术领域
本发明涉及防血凝块附着剂。此外,本发明涉及使用了所述防血凝块附着剂的血液采集容器。
背景技术
临床检查中,为了采集血液样品而广泛使用了采血管等的血液采集容器。将血液采集至容纳有血清分离用组合物的血液采集容器中,使血液凝固后进行离心分离,能够将血液分为血清和血凝块。此时,血清位于血清分离用组合物的上侧,血凝块位于下侧。
通过使用涂布有血凝块不易附着的成分的血液采集容器,而能够在离心分离后,抑制血凝块附着于所述血清分离用组合物的上侧的血液采集容器的内壁面。
作为所述血凝块不易附着的成分,下述的专利文献1中记载有硅油等。
现有技术文献
专利文献
专利文献1:日本特开昭56-104644号公报
发明内容
发明所解决的技术问题
在以往的血液采集容器中,将血液分为血清和血凝块后,血凝块可能会附着在血清分离用组合物的上侧的血液采集容器的内壁面上。在专利文献1所述的包含硅油等血凝块不易附着的成分的层存在于血液采集容器的内壁面上的情况下,虽然能够在一定程度上抑制血凝块附着在该内壁面上,但是其效果仍不充分。
此外,在为了充分抑制血凝块的附着而简单地提高硅油等的混合量的情况下,硅油等可能从血液采集容器的内壁面上剥离,成为油滴和油膜而漂浮在血清表面。这些油滴、油膜附着在自动分析装置的检体吸取管嘴时,可能会导致喷嘴的狭窄、堵塞,阻碍准确的检体吸取。
在血液采集容器的内壁面上附着的血凝块与血清接触的情况下,该血凝块中的源自血细胞的成分可能混入血清中,在使用了该血清的检查中导致测定精度降低。例如,在血液采集容器的内壁面上附着的血凝块与血清接触的情况下,血凝块中的来自血细胞成分的内容物混入血清中,使血清发生溶血,其结果,对钾等的检查值造成影响。此外,例如,在血液采集容器的内壁面上附着的血凝块与血清接触的情况下,血清中的成分可能混入血细胞中,使得血清中的该成分的浓度发生变化,对该成分的检查值产生影响。
本发明的目的在于,提供能够抑制血凝块附着至血液采集容器的内壁面的防血凝块附着剂。此外,本发明的目的还在于,提供使用了所述防血凝块附着剂的血液采集容器。
解决问题的技术手段
根据本发明的广泛方案,可提供一种防血凝块附着剂,其包含:聚醚化合物或硅油;氨基酸。
在本发明的防血凝块附着剂的一个特定方案中,所述防血凝块附着剂包含所述聚醚化合物。
本发明的防血凝块附着剂的一个特定方案中,所述聚醚化合物为聚丙二醇或聚丙二醇衍生物。
本发明的防血凝块附着剂的一个特定方案中,所述防血凝块附着剂包含所述硅油。
本发明的防血凝块附着剂的一个特定方案中,所述硅油为改性硅油。
本发明的防血凝块附着剂的一个特定方案中,所述氨基酸包含丙氨酸、甘氨酸、天冬酰胺或丝氨酸。
本发明的防血凝块附着剂的一个特定方案中,所述氨基酸为β-丙氨酸。
本发明的防血凝块附着剂的一个特定方案中,所述防血凝块附着剂包含血液凝固促进成分。
本发明的防血凝块附着剂的一个特定方案中,所述血液凝固促进成分包含二氧化硅粉末。
本发明的防血凝块附着剂的一个特定方案中,所述血液凝固促进成分包含凝血酶或凝血酶样酶。
根据本发明的广泛方案,可提供一种血液采集容器,其具备血液采集容器主体和形成在所述血液采集容器主体的内壁面上的防血凝块附着层,其中,所述防血凝块附着层由所述防血凝块附着剂形成。
本发明的血液采集容器的一个特定方案中,所述血液采集容器具备容纳在所述血液采集容器主体的底部的血清分离用组合物。
发明的效果
本发明的防血凝块附着剂包含:聚醚化合物或硅油;氨基酸,因此能够抑制血凝块附着至血液采集容器的内壁面。
附图说明
[图1]图1是示意性地表示使用了本发明的一实施方式的防血凝块附着剂的血液采集容器的正视截面图。
本发明的具体实施方式
以下,对于本发明详细地进行说明。
本发明的防血凝块附着剂包含:聚醚化合物或硅油;氨基酸。
本发明的防血凝块附着剂可包含聚醚化合物、硅油、或聚醚化合物和硅油这两者。
在本发明的防血凝块附着剂的情况下,由于具备所述构成,因此能够抑制血凝块附着至血液采集容器的内壁面。在本发明的防血凝块附着剂的情况下,能够在不增多硅油等的以往公知的防血凝块附着成分的情况下,抑制血凝块附着至血液采集容器的内壁面。
此外,就本发明的防血凝块附着剂而言,防血凝块附着剂不易从血液采集容器的内壁面剥离,不易成为油滴和油膜而漂浮在血清表面。
以下,对于本发明的防血凝块附着剂中使用的各成分的详细等进行说明。
(聚醚化合物)
作为所述聚醚化合物,可使用以往公知的聚醚化合物。所述聚醚化合物,可以仅使用一种,或组合使用两种以上。
作为所述聚醚化合物,可举出聚氧亚烷基二醇、聚氧亚烷基二醇衍生物和水难溶性聚氧亚烷基衍生物等。
作为所述聚氧亚烷基二醇,可举出聚四亚甲基醚二醇、聚乙二醇、聚环氧乙烷、聚丙二醇、聚氧乙烯聚氧丙二醇和聚乙烯醇等。
作为所述聚氧亚烷基二醇衍生物,可举出聚丙二醇衍生物等的聚氧亚烷基二醇醚和聚氧亚烷基烷基醚等。
作为所述聚丙二醇衍生物,可举出聚氧丙烯甘油基醚、聚丙二醇二甲醚、聚氧乙烯聚氧丙烯烷基醚、聚氧乙烯聚氧丙二醇和聚氧丙烯烷基醚等。
作为所述水难溶性聚氧亚烷基衍生物,可举出以往公知的聚氧亚烷基与各种化合物衍生而成的衍生物。作为所述水难溶性聚氧亚烷基衍生物,可举出聚氧亚烷基的丁醇衍生物和聚氧亚烷基的丙三醇衍生物等。
从进一步有效地抑制血凝块的附着的观点出发,所述聚醚化合物优选为聚醚类表面活性剂。
从更进一步有效地抑制血凝块的附着的观点出发,所述聚醚化合物优选为聚亚烷基二醇或聚亚烷基二醇衍生物,更优选为聚丙二醇或聚丙二醇衍生物。
在所述防血凝块附着剂包含所述聚醚化合物的情况下,所述防血凝块附着剂100重量%中,所述聚醚化合物的含量优选为0.01重量%以上,更优选为0.1重量%以上,优选为10重量%以下,更优选为5重量%以下。所述聚醚化合物的含量为所述下限以上时,能够进一步有效地抑制血凝块的附着。所述聚醚化合物的含量为所述上限以下时,能够有效地抑制血清表面的油滴和油膜等的产生。
(硅油)
作为所述硅油,可使用以往公知的硅油。所述硅油,可以仅使用一种,或组合使用两种以上。
作为所述硅油,可举出二甲基聚硅氧烷和甲基氢二烯聚硅氧烷等的脂肪族硅油、以及甲基苯基聚硅氧烷等的芳香族硅油等。
所述硅油可以为导入极性基团而对亲水性进行了改性的改性硅油。作为所述极性基团,可举出羟基、氨基、羧基、环氧基和醚基等。
从更有效地抑制血凝块的附着的观点出发,所述硅油优选为改性硅油。
从进一步有效地抑制血凝块的附着的观点出发,所述硅油优选为硅油类表面活性剂。
所述硅油优选为二甲基聚硅氧烷或改性二甲基聚硅氧烷,更优选为改性二甲基聚硅氧烷,进一步优选为具有醚基或氨基的改性二甲基聚硅氧烷,特别优选为具有醚基的改性二甲基聚硅氧烷。在这种情况下,更能够进一步有效地抑制血凝块的附着。
作为所述具有醚基的改性二甲基聚硅氧烷的市售品,例如,可举出BY16-201、SF8410、SF8427、SF8428、FZ-2162、SH3746、SH3749、FZ-77、L-7001、Y7006、FZ-2104、FZ-2110、SH8400、SH8410、SH3773M、FZ-2207、FZ-2203、FZ-2222和FZ-2208(DOW CORNING TORAY公司制)等。
在所述防血凝块附着剂包含所述硅油的情况下,所述防血凝块附着剂100重量%中,所述硅油的含量优选为0.01重量%以上,更优选为0.1重量%以上,优选为10重量%以下,更优选为5重量%以下。所述硅油的含量为所述下限以上时,能够进一步有效地抑制血凝块的附着。所述硅油的含量为所述上限以下时,能够有效地抑制血清表面的油滴和油膜等的产生。
所述防血凝块附着剂100重量%中,所述聚醚化合物和所述硅油的总含量优选为0.01重量%以上,更优选为0.1重量%以上,优选为10重量%以下,更优选为5重量%以下。所述总含量为所述下限以上时,能够进一步有效地抑制血凝块的附着。所述总含量为所述上限以下时,能够有效地抑制血清中的油滴和油膜等的产生。
(氨基酸)
所述防血凝块附着剂包含氨基酸。作为所述氨基酸,可使用以往公知的氨基酸。所述氨基酸,可以仅使用一种,或组合使用两种以上。
作为所述氨基酸,可举出精氨酸、天冬酰胺、天冬氨酸、谷氨酰胺、谷氨酸、组氨酸、赖氨酸、丝氨酸和苏氨酸等的亲水性氨基酸、以及丙氨酸、甘氨酸、半胱氨酸、异亮氨酸、亮氨酸、甲硫氨酸、苯基丙氨酸、脯氨酸、色氨酸、酪氨酸和缬氨酸等的疏水性氨基酸等。
所述氨基酸可以为亲水性氨基酸或疏水性氨基酸。此外,所述氨基酸可以为D-氨基酸或L-氨基酸。此外,所述氨基酸可以为α-氨基酸或β-氨基酸。
从进一步有效地抑制血凝块的附着的观点出发,所述氨基酸优选包含丙氨酸、甘氨酸、天冬酰胺或丝氨酸,更优选包含丙氨酸或天冬酰胺。
从更进一步有效地抑制血凝块的附着的观点出发,所述氨基酸优选为β-丙氨酸。
所述防血凝块附着剂100重量%中,所述氨基酸的含量优选为0.5重量%以上,更优选为1重量%以上,优选为10重量%以下,更优选为5重量%以下。所述氨基酸的含量为所述下限以上时,能够进一步有效地抑制血凝块的附着。所述氨基酸的含量为所述上限以下时,涂布在血液采集容器的内壁面时,所述防血凝块附着剂不易析出,因此不易堵塞涂布喷嘴。
所述防血凝块附着剂包含所述聚醚化合物的情况下,所述氨基酸的含量相对于所述聚醚化合物的含量的重量比(所述氨基酸的含量/所述聚醚化合物的含量)优选为1以上,更优选为3以上,进一步优选为5以上,优选为15以下。所述重量比为所述下限以上和所述上限以下时,能够进一步有效地抑制血凝块的附着。
所述防血凝块附着剂包含所述硅油的情况下,所述氨基酸的含量相对于所述硅油的含量的重量比(所述氨基酸的含量/所述硅油的含量)优选为1以上,更优选为3以上,进一步优选为5以上,优选为15以下。所述重量比为所述下限以上和所述上限以下时,能够进一步有效地抑制血凝块的附着。
所述氨基酸的含量相对于所述聚醚化合物和所述硅油的总含量的重量比(所述氨基酸的含量/所述聚醚化合物和所述硅油的总含量)优选为1以上,更优选为3以上,进一步优选为5以上,优选为15以下。所述重量比为所述下限以上和所述上限以下时,能够进一步有效地抑制血凝块的附着。
[血液凝固促进成分]
所述防血凝块附着剂可包含血液凝固促进成分。通过使所述防血凝块附着剂包含血液凝固促进成分,能够促进血液凝固,缩短血液凝固时间。
作为所述血液凝固促进成分,可使用以往公知的血液凝固促进成分。作为所述血液凝固促进成分,例如,可举出无机粉末、凝血酶和蛇毒等的凝血酶样酶等。所述血液凝固促进成分,可以仅使用一种,或组合使用两种以上。
从有效地使血液凝固的观点出发,所述血液凝固促进成分优选包含无机粉末、凝血酶或凝血酶样酶。
作为所述无机粉末,可举出二氧化硅粉末、玻璃粉末、高岭土粉末、Cel ite粉末和膨润土粉末等。
从良好地使血液凝固的观点出发,所述无机粉末优选为二氧化硅粉末。
所述无机粉末的平均粒径优选为10nm以上,更优选为100nm以上,优选为1mm以下,更优选为100μm以下。所述无机粉末的平均粒径为所述下限以上和所述上限以下时,能够使血液在短时间内良好地凝固。所述无机粉末的平均粒径为所述上限以下时,能够有效地抑制所述防血凝块附着剂中的所述无机粉末的沉淀。
作为所述无机粉末的平均粒径,采用成为50%的中值粒径(d50)的值。所述平均粒径可使用激光衍射散射方式的粒度分布测定装置进行测定。
所述防血凝块附着剂100重量%中,所述无机粉末的含量优选为0.5重量%以上,更优选为1重量%以上,优选为10重量%以下,更优选为5重量%以下。所述无机粉末的含量为所述下限以上时,能够使血液在短时间内良好地凝固。所述无机粉末的含量为所述上限以下时,能够有效地抑制所述防血凝块附着剂中的所述无机粉末的沉淀。
所述防血凝块附着剂100重量%中的所述凝血酶和所述凝血酶样酶的含量可进行适宜变更。
[溶剂]
所述防血凝块附着剂优选包含溶解介质(溶剂)。通过所述溶剂的使用,能够将防血凝块附着剂的粘度控制为适宜范围,提高防血凝块附着剂的涂布性。所述溶剂,可以仅使用一种,或组合使用两种以上。
作为所述溶剂,可举出水、甲醇、乙醇、丁醇、异丙醇、己烷等。
所述防血凝块附着剂中的所述溶剂的含量没有特别限定。考虑到所述防血凝块附着剂的涂布性,所述溶剂的含量可进行适宜变更。
[其他成分]
为了改善对于血液采集容器的附着性、涂布性和血液凝固性能等,所述防血凝块附着剂可包含水溶性粘合剂、蛋白酶抑制剂和抗纤维溶解剂等的其他成分。所述其他成分分别可以仅使用一种,或组合使用两种以上。
作为所述水溶性粘合剂,可举出聚乙烯醇、聚乙烯基吡咯烷酮、丙烯酸类共聚物、聚氧亚烷基嵌段共聚物等。
作为所述蛋白酶抑制剂,可举出抑肽酶和大豆胰朊酶抑制剂等。
作为所述抗纤维溶解剂,可举出ε-氨基己酸、氨基甲基苯甲酸和氨基甲基环己烷羧酸等。
(防血凝块附着剂的其他详细)
本发明的防血凝块附着剂优选涂布在血液采集容器主体的内壁面上进行使用。本发明的防血凝块附着剂可适用于在血液采集容器中形成防血凝块附着层。
所述防血凝块附着剂,例如,可通过将所述聚醚化合物或所述硅油、所述氨基酸、所述血液凝固促进成分、所述其他成分以及所述溶剂进行混合来制造。
(血液采集容器)
所述血液采集容器具备血液采集容器主体、和形成在所述血液采集容器主体的内壁面上的防血凝块附着层,所述防血凝块附着层由所述防血凝块附着剂形成。
所述血液采集容器主体的材料没有特别限定。作为所述血液采集容器主体的材料,可举出玻璃、聚对苯二甲酸乙二醇酯和聚丙烯等。
所述血液采集容器主体,优选在一端具有开口端。优选封闭所述血液采集容器主体的另一端。
所述血液采集容器,可通过在血液采集容器主体的内壁面涂布所述防血凝块附着剂来制造。所述涂布的方法,没有特别限定。作为所述涂布的方法,可举出喷涂涂布和浸渍涂布法等。优选在血液采集容器主体的内壁面涂布所述防血凝块附着剂后,使其干燥,除去所述溶剂,从而形成防血凝块附着层。
因此,所述防血凝块附着层优选为将所述防血凝块附着剂中的所述溶剂除去而得到的层。所述防血凝块附着层优选为所述防血凝块附着剂的干燥物层。
所述防血凝块附着层可以形成在所述血液采集容器主体的整个内壁面上。所述防血凝块附着层优选形成在所述血液采集容器主体的侧面部的内壁面上。所述防血凝块附着层可以形成在所述血液采集容器的侧面部的整个内壁面上,也可以形成在所述血液采集容器的侧面部的部分内壁面上。
所述防血凝块附着层可以为连续层或不连续层。所述防血凝块附着层可以以分散状态而形成在所述血液采集容器主体的内壁面上。所述防血凝块附着层可以在所述血液采集容器主体的内壁面上形成为点状等的岛状。如上所述,在以分散状态而形成在所述血液采集容器主体的内壁面上或形成为岛状的不连续层的情况下,本发明中也视为层。
在所述防血凝块附着层包含所述聚醚化合物的情况下,所述防血凝块附着层中,所述氨基酸的含量相对于所述聚醚化合物的含量的重量比(所述氨基酸的含量/所述聚醚化合物的含量)优选为1以上,更优选为3以上,进一步优选为5以上,优选为15以下。所述重量比为所述下限以上和所述上限以下时,能够进一步有效地抑制血凝块的附着。
所述防血凝块附着层包含所述硅油的情况下,所述防血凝块附着层中,所述氨基酸的含量相对于所述硅油的含量的重量比(所述氨基酸的含量/所述硅油的含量)优选为1以上,更优选为3以上,进一步优选为5以上,优选为15以下。所述重量比为所述下限以上和所述上限以下时,能够进一步有效地抑制血凝块的附着。
所述防血凝块附着层中,所述氨基酸的含量相对于所述聚醚化合物和所述硅油的总含量的重量比(所述氨基酸的含量/所述聚醚化合物和所述硅油的总含量)优选为1以上,更优选为3以上,进一步优选为5以上,优选为15以下。所述重量比为所述下限以上和所述上限以下时,能够进一步有效地抑制血凝块的附着。
所述血液采集容器优选具备容纳在所述血液采集容器主体的底部的血清分离用组合物。
作为所述血清分离用组合物,可使用以往公知的血清分离用组合物。作为所述血清分离用组合物,例如,可举出WO2011/105151A1等所述的血清分离用组合物。
所述血清分离用组合物,在离心分离时在血清层和血凝块层之间移动而形成隔壁,而用于防止血凝块层和血清层的成分迁移。
所述血液采集容器优选具备栓体。作为所述栓体,可使用以往公知的栓体。所述栓体,可具备橡胶栓等的栓主体和帽盖部件。
图1是示意性地表示使用了本发明的一实施方式的防血凝块附着剂的血液采集容器的正视截面图。
图1表示的血液采集容器11具备血液采集容器主体2、防血凝块附着层1、血清分离用组合物3以及栓体4。在血液采集容器主体2的侧面部的内壁面2a上形成有防血凝块附着层1。血液采集容器主体2的底部容纳有血清分离用组合物3。血液采集容器主体2的开口端安装有栓体4。需要说明的是,所述防血凝块附着层可以形成在所述血液采集容器主体的整个内壁面上或形成在所述血液采集容器主体的部分内壁面上。此外,所述防血凝块附着层,如上所述,可以以分散状态而形成在所述血液采集容器主体的内壁面上,或以点状等的岛状而形成在所述血液采集容器主体的内壁面上。
所述血液采集容器主体优选为采血管主体。所述血液采集容器优选为采血管。
所述血液采集容器的内压没有特别限定。所述血液采集容器可以是对内部进行了排气的基础上用所述栓体进行密封而得到的真空血液采集容器(真空采血管)。在采用真空采血管的情况下,能够不取决于采血者的技术差而简便地进行一定程度的血液采集。
从防止细菌感染的观点出发,所述血液采集容器的内部优选基于ISO和JIS所述的基准而进行了灭菌。
从血液分离血清时,将血液采集至容纳有血清分离用组合物的血液采集容器的内部后,通过离心分离装置进行离心分离。通过离心分离,使血液中的细胞成分和血液凝固成分等沉降至下方(血凝块),作为上清液而分离血清。此时,所述血清分离用组合物位于这些的中间层,并形成隔离血凝块和血清的隔壁。
以下,通过举出实施例和比较例来对本发明具体性地进行说明。本发明不限于以下的实施例。
准备以下的血液采集容器主体。
具有图1表示的形状的血液采集容器主体
内径10.8mm×长度100mm(长度:一端(开口端)和另一端的距离)
材料:聚对苯二甲酸乙二醇酯
准备以下的栓体。
具有图1表示的形状的栓体
栓主体:橡胶栓(材料:丁基橡胶)
以下述方式制备血清分离用组合物。
将环戊二烯类低聚物(EXXON MOBIL公司制,商品名:ESCOREZ5690)、偏苯三酸酯(大日本油墨化学工业公司制,商品名:MONOSIZER W700)在130℃下溶解,制备液态树脂成分。向该液态树脂成分中,作为聚亚烷基聚醚,溶解聚丙烯聚醚(NOF公司制,商品名:UNIOLD700),冷却至约30℃。接下来,作为无机粉末,将亲水性二氧化硅微粉(日本AEROSIL公司制,商品名:AEROSIL 200CF)和疏水性二氧化硅微粉(日本AEROSIL公司制,商品名:AEROSILR974)添加至液态树脂成分中,通过行星式混合机进行搅拌的同时,使其分散。由此,制备血清分离用组合物。
准备以下的防血凝块附着剂的材料。
(聚醚化合物)
聚丙二醇(ADEKA公司制“ADEKAPolyester G4000”)
(硅油)
具有醚基的改性二甲基聚硅氧烷(DOW CORNING TORAY公司制“SF8410”)
(氨基酸)
β-丙氨酸
L-天冬酰胺
L-丝氨酸
L-甘氨酸
(血液凝固促进成分)
二氧化硅粉末(平均粒径5μm)
(实施例1)
防血凝块附着剂的制备:
以表1表示的混合量混合聚丙二醇、β-丙氨酸、二氧化硅粉末以及水(溶剂),制备防血凝块附着剂。
血液采集容器的制备:
将血清分离用组合物0.9g容纳至血液采集容器主体的底部。接着,在血液采集容器主体的内壁面涂布得到的防血凝块附着剂后,干燥,而形成防血凝块附着层。接着,将血液采集容器主体减压至12kPa,用栓体进行密封而制备血液采集容器。
(实施例2~7)
将防血凝块附着剂的组成如表1表示的进行变更,除此之外,以与实施例1同样的方式制备防血凝块附着剂和血液采集容器。
(比较例1)
未使用氨基酸,除此之外,以与实施例1同样的方式制备防血凝块附着剂和血液采集容器。
(比较例2)
未使用氨基酸,除此之外,以与实施例7同样的方式制备防血凝块附着剂和血液采集容器。
(评价)
(1)血凝块附着量
将血液1mL采集至得到的血液采集容器,进行旋转混合而使血液附着至血液采集容器的内壁面的整个面上。通过离心分离装置以1500G进行10分钟的离心操作。离心分离后的血液采集容器中,血清位于上方,血凝块位于下方,血清分离用组合物位于他们的中间层,形成隔离血凝块和血清的隔壁。
打开所述血液采集容器,除去血清后,添加水0.5mL,再次用橡胶栓密封。然后,进行旋转混合,将该血液采集容器的内壁面上附着的血凝块在添加的水中溶血后,回收液体。
使用自动分析装置(HITACHI HIGH-TECHNOLOGIES公司制“7170S”),对回收得到的液体在波长415nm处的吸光度进行测定。需要说明的是,所述吸光度的值越大,表明回收得到的液体中血细胞成分越多地溶血。即,所述吸光度的值越大,表明所述离心分离后附着在血液采集容器的内壁面的血凝块的量越多。因此,所述吸光度的值越小,则防血凝块附着效果越优异。
组成和结果如下述的表1表示。
符号说明
1…防血凝块附着层
2…血液采集容器主体
2a…内壁面
3…血清分离用组合物
4…栓体
11…血液采集容器
Claims (8)
1.一种防血凝块附着剂,其包含:
聚醚化合物;和
氨基酸,
所述聚醚化合物为聚丙二醇或聚丙二醇衍生物,
所述氨基酸的含量与所述聚醚化合物的含量的重量比为3以上15以下。
2.根据权利要求1所述的防血凝块附着剂,其中,
所述氨基酸包含丙氨酸、甘氨酸、天冬酰胺或丝氨酸。
3.根据权利要求1所述的防血凝块附着剂,其中,
所述氨基酸为β-丙氨酸。
4.根据权利要求1~3中任一项所述的防血凝块附着剂,其包含血液凝固促进成分。
5.根据权利要求4所述的防血凝块附着剂,其中,
所述血液凝固促进成分包含二氧化硅粉末。
6.根据权利要求4所述的防血凝块附着剂,其中,
所述血液凝固促进成分包含凝血酶或凝血酶样酶。
7.一种血液采集容器,其具备:
血液采集容器主体;和
形成在所述血液采集容器主体的内壁面上的防血凝块附着层,
所述防血凝块附着层由权利要求1~6中任一项所述的防血凝块附着剂形成。
8.根据权利要求7所述的血液采集容器,其具备容纳在所述血液采集容器主体的底部的血清分离用组合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-016753 | 2019-02-01 | ||
JP2019016753 | 2019-02-01 | ||
PCT/JP2020/003126 WO2020158787A1 (ja) | 2019-02-01 | 2020-01-29 | 血餅付着防止剤及び血液採取容器 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113329691A CN113329691A (zh) | 2021-08-31 |
CN113329691B true CN113329691B (zh) | 2024-09-03 |
Family
ID=71841456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080010053.5A Active CN113329691B (zh) | 2019-02-01 | 2020-01-29 | 防血凝块附着剂和血液采集容器 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220133961A1 (zh) |
EP (1) | EP3918992A4 (zh) |
JP (1) | JP6747744B1 (zh) |
KR (1) | KR20210124175A (zh) |
CN (1) | CN113329691B (zh) |
WO (1) | WO2020158787A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101137902A (zh) * | 2005-03-17 | 2008-03-05 | 积水化学工业株式会社 | 血液凝固促进剂及血液检查用容器 |
CN102132140A (zh) * | 2008-08-28 | 2011-07-20 | 积水医疗株式会社 | 血液采集容器 |
CN102656213A (zh) * | 2009-12-24 | 2012-09-05 | 东丽株式会社 | 具有抗血液凝固作用的亲水性高分子化合物 |
JP2015197362A (ja) * | 2014-04-01 | 2015-11-09 | 積水メディカル株式会社 | 血液凝固促進剤、血液採取容器及び甲状腺刺激ホルモンの測定方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS596655B2 (ja) | 1980-01-28 | 1984-02-14 | 積水化学工業株式会社 | 血清分離用採血管 |
CA2007620A1 (en) * | 1990-02-11 | 1991-07-11 | Charles Terrence Macartney | Biological sample collection tube |
JP2000292421A (ja) * | 1999-04-06 | 2000-10-20 | Terumo Corp | 血液処理方法及び採血管 |
JP2001079065A (ja) * | 1999-09-13 | 2001-03-27 | Terumo Corp | 血液成分保存容器 |
US7595028B2 (en) * | 2002-05-29 | 2009-09-29 | Sekisui Chemical Co., Ltd. | Bottomed tube for blood examination, stopper of bottomed tube for blood examination and blood examination container |
WO2004097407A1 (ja) * | 2003-04-25 | 2004-11-11 | Sekisui Chemical Co., Ltd. | 血液凝固促進剤及び採血管 |
JP2007248175A (ja) * | 2006-03-15 | 2007-09-27 | Sekisui Chem Co Ltd | 血液検査用容器 |
JP4914115B2 (ja) * | 2006-05-12 | 2012-04-11 | 積水化学工業株式会社 | 血液検査用容器 |
JP4852479B2 (ja) * | 2007-06-05 | 2012-01-11 | 積水化学工業株式会社 | 血液凝固促進剤含有組成物及び血液検査用容器 |
WO2010024326A1 (ja) * | 2008-08-28 | 2010-03-04 | 積水メディカル株式会社 | 血液検査容器の製造方法、血液検査容器及びスプレー装置 |
WO2011105151A1 (ja) | 2010-02-26 | 2011-09-01 | 積水メディカル株式会社 | 血清または血漿分離用組成物及び血液検査用容器 |
JP5373075B2 (ja) * | 2010-02-26 | 2013-12-18 | 積水メディカル株式会社 | 血液分離剤及び血液採取容器 |
EP2562228A4 (en) * | 2010-04-20 | 2014-01-15 | Nitto Denko Corp | WATER DISPERSIBLE ACRYLIC ADHESIVE COMPOSITION AND ADHESIVE FILM THEREOF |
WO2012077702A1 (ja) * | 2010-12-09 | 2012-06-14 | 積水メディカル株式会社 | 採血管、採血管の製造方法及び血液試料の調製方法 |
TW201311774A (zh) * | 2011-06-23 | 2013-03-16 | Toray Industries | 具有抗血液凝固作用的疏水性高分子化合物 |
WO2016159236A1 (ja) * | 2015-03-31 | 2016-10-06 | 積水メディカル株式会社 | 血清または血漿分離用組成物、並びに血液採取容器 |
-
2020
- 2020-01-29 JP JP2020519821A patent/JP6747744B1/ja active Active
- 2020-01-29 KR KR1020217012988A patent/KR20210124175A/ko unknown
- 2020-01-29 WO PCT/JP2020/003126 patent/WO2020158787A1/ja unknown
- 2020-01-29 US US17/426,014 patent/US20220133961A1/en active Pending
- 2020-01-29 CN CN202080010053.5A patent/CN113329691B/zh active Active
- 2020-01-29 EP EP20748851.1A patent/EP3918992A4/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101137902A (zh) * | 2005-03-17 | 2008-03-05 | 积水化学工业株式会社 | 血液凝固促进剂及血液检查用容器 |
CN102132140A (zh) * | 2008-08-28 | 2011-07-20 | 积水医疗株式会社 | 血液采集容器 |
CN102656213A (zh) * | 2009-12-24 | 2012-09-05 | 东丽株式会社 | 具有抗血液凝固作用的亲水性高分子化合物 |
JP2015197362A (ja) * | 2014-04-01 | 2015-11-09 | 積水メディカル株式会社 | 血液凝固促進剤、血液採取容器及び甲状腺刺激ホルモンの測定方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20210124175A (ko) | 2021-10-14 |
EP3918992A4 (en) | 2022-10-19 |
JP6747744B1 (ja) | 2020-08-26 |
US20220133961A1 (en) | 2022-05-05 |
JPWO2020158787A1 (ja) | 2021-02-18 |
CN113329691A (zh) | 2021-08-31 |
EP3918992A1 (en) | 2021-12-08 |
WO2020158787A1 (ja) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102132140B (zh) | 血液采集容器 | |
CN110753843B (zh) | 血清或血浆分离用组合物、血液采取容器以及血清或血浆的分离方法 | |
EP4071470A1 (en) | Blood collection container and plasma separation method | |
EP2410329B1 (en) | Composition for plasma and serum separation, and container for blood testing | |
EP3054001A1 (en) | Device for concentration and separation of circulating tumor cells, and method for concentration and separation of circulating tumor cells | |
WO2007072144A2 (en) | Plastic test tube for taking blood samples | |
EP4119943A1 (en) | Leukocyte concentration separation device, blood collection container, and method for separating leukocytes | |
JP3063799B2 (ja) | 血液分離剤 | |
CN113329691B (zh) | 防血凝块附着剂和血液采集容器 | |
US4514091A (en) | Container assembly for viscous test specimen materials | |
KR100740406B1 (ko) | 혈액 응고 촉진제 및 채혈관 | |
JP6809747B1 (ja) | 単核球含有血漿分離用組成物及び血液採取容器 | |
JP2004136236A (ja) | 分注用チップ | |
JP3836446B2 (ja) | 血液検査用有底管、血液検査用有底管の栓体及び血液検査用容器 | |
JPS59221666A (ja) | 血液分離管 | |
JPH02277460A (ja) | 採液管 | |
CN118235042A (zh) | 血液采集容器、血浆的分离方法、细胞外游离核酸的分离方法和细胞外囊泡的分离方法 | |
JPH02305554A (ja) | 液体試料微量採取管 | |
JP2000146955A (ja) | 血液検査用容器 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230721 Address after: Tokyo, Japan Applicant after: SEKISUI MEDICAL Co.,Ltd. Address before: Tokyo, Japan Applicant before: SEKISUI MEDICAL Co.,Ltd. Applicant before: TOKUYAMA SEKISUI Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |